Realistic illustration of MRAP2 protein supporting MC3R receptor in cellular appetite signaling, highlighting role in obesity-related mutations.
Realistic illustration of MRAP2 protein supporting MC3R receptor in cellular appetite signaling, highlighting role in obesity-related mutations.
Immagine generata dall'IA

Tiny protein MRAP2 supports appetite-related signaling

Immagine generata dall'IA
Verificato

Researchers have shown that a helper protein called MRAP2 is crucial for the function of an appetite‑related receptor known as MC3R. The study, led by the University of Birmingham and published in Science Signaling, helps explain how genetic mutations in MRAP2 found in some people with obesity can weaken cellular signaling involved in energy balance, offering clues for future treatments.

A new study details the role of MRAP2, a small accessory protein, in regulating how the body handles hunger and energy. According to the University of Birmingham summary of the work, published in Science Signaling on December 16, an international research team showed that MRAP2 directly supports MC3R (melanocortin‑3 receptor), a receptor involved in energy homeostasis.

Using human hypothalamus transcriptomic data and cell‑based models, the scientists demonstrated that MRAP2 and MC3R are co‑expressed in neurons linked to energy balance and appetite control, and that MRAP2 physically interacts with MC3R. In HEK293 cell experiments, MRAP2 enhanced MC3R cyclic AMP (cAMP) signaling, impaired β‑arrestin recruitment, and reduced receptor internalization, helping sustain MC3R activity.

The team also examined how the relative amounts of the two proteins affect signaling. When MRAP2 was present at levels comparable to MC3R, MRAP2 boosted MC3R‑driven signaling, supporting the receptor’s role in balancing energy intake with energy use. Structural modeling, combined with alanine mutagenesis, identified specific transmembrane residues in MRAP2 and MC3R that are important for this regulatory effect.

Further experiments tested MRAP2 genetic variants previously identified in individuals who are overweight or obese. These altered forms of MRAP2 failed to enhance MC3R‑mediated signaling in the cell models, suggesting that such variants can disrupt hormone‑based pathways that normally help maintain energy balance and appetite control.

Dr. Caroline Gorvin, associate professor at the University of Birmingham and lead author, said in a statement released by the university: "The findings give us some important insights into what's going on in the hormonal system, related to some key functions like energy balance, appetite, and puberty timing.

"The identification of this protein, MRAP2, as a key aide or supporter to these essential appetite‑regulating proteins also gives us new clues for people who have a genetic predisposition to obesity, and how MRAP2 mutations are a clear indication of risk."

The work was carried out through the University of Birmingham’s Department of Metabolism and Systems Science and the Centre of Membrane Proteins and Receptors (COMPARE), a joint research centre involving the Universities of Birmingham and Nottingham that focuses on how cells communicate in health and disease.

By clarifying MRAP2’s role in MC3R signaling and highlighting the impact of obesity‑associated MRAP2 variants, the study points to potential targets for future drugs aimed at modulating appetite‑related pathways. Researchers hope such approaches could, in time, complement lifestyle interventions for managing weight and metabolic health.

The full study, titled "The accessory protein MRAP2 directly interacts with melanocortin‑3 receptor to enhance signaling," appears in Science Signaling (2025; 18(917)), DOI: 10.1126/scisignal.adu4315.

Cosa dice la gente

Discussions on X about the MRAP2 protein study are sparse and recent, primarily consisting of neutral summaries and shares from science accounts and media outlets in English, French, and Turkish. Posters highlight MRAP2's essential role in MC3R signaling for appetite and energy balance, linking mutations to obesity, with mild optimism about potential treatments. No significant negative, skeptical, or in-depth debate found.

Articoli correlati

Scientists in a lab boosting MeCP2 protein levels to treat Rett syndrome, showing restored neurons and mouse models.
Immagine generata dall'IA

Scientists raise MeCP2 levels by shifting MECP2 splicing in early Rett syndrome studies

Riportato dall'IA Immagine generata dall'IA Verificato

Researchers at Texas Children’s Hospital’s Duncan Neurological Research Institute and Baylor College of Medicine report an experimental gene-targeting approach designed to increase levels of the MeCP2 protein disrupted in Rett syndrome. In mouse experiments and neurons derived from patient cells, the strategy boosted MeCP2 and partially restored cellular structure, electrical activity and gene-expression patterns, according to findings published in Science Translational Medicine.

Researchers in Dresden have discovered that the protein MCL1, known for helping cancer cells evade death, also regulates their energy production through the mTOR pathway. This dual role explains why drugs targeting MCL1 can fight tumors but sometimes harm the heart. The team has developed a dietary approach to mitigate this cardiotoxicity, paving the way for safer therapies.

Riportato dall'IA Verificato

University of Tsukuba researchers report that CtBP2, a metabolic sensor protein detected in the bloodstream, tracks with age and health status in people—declining with age, remaining higher in members of long‑lived families, and falling in those with advanced diabetic complications.

Researchers working at Harvard University and collaborators in Brazil have identified metabolites produced by gut bacteria that travel through the portal vein to the liver and appear to influence energy use and insulin sensitivity in mice. The findings, published in Cell Metabolism, suggest possible new strategies for preventing or treating obesity and type 2 diabetes by targeting gut–liver communication.([sciencedaily.com](https://www.sciencedaily.com/releases/2025/12/251214100926.htm?utm_source=openai))

Riportato dall'IA

Researchers have uncovered how amyloid beta and inflammation may both trigger synapse pruning in Alzheimer's disease through a common receptor, potentially offering new treatment avenues. The findings challenge the notion that neurons are passive in this process, showing they actively erase their own connections. Led by Stanford's Carla Shatz, the study suggests targeting this receptor could preserve memory more effectively than current amyloid-focused drugs.

Researchers at Cold Spring Harbor Laboratory report they have identified a three-part molecular circuit involving SRSF1, Aurora kinase A (AURKA) and MYC that helps drive aggressive pancreatic ductal adenocarcinoma. In laboratory models, a splice-switching antisense oligonucleotide designed to alter AURKA splicing disrupted the circuit, reducing tumor-cell viability and triggering programmed cell death.

Riportato dall'IA Verificato

Researchers at Georgetown University Medical Center report that shifts in the brain protein KCC2 can change how strongly everyday cues become linked to rewards. In a study published December 9 in Nature Communications, they show that reduced KCC2 activity in rats is associated with intensified dopamine neuron firing and stronger cue–reward learning, offering clues to mechanisms that may also be involved in addiction and other psychiatric disorders.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta